Skip to content
Biotechnology, Medical Health Aged Care

Celebrating 25-years and $31 million of impact and innovation in dementia research

Dementia Australia 3 mins read

Celebrating 25-years and $31 million of impact and innovation in dementia research

Dementia Australia Research Foundation is marking 25 years of supporting Australia’s best emerging researchers to explore, innovate and advance the field of dementia research with the release of its More than a Cure: 25 Years of Impact report.

The report highlights some of the more than 380 game-changing research projects that have advanced because of more than $31 million from Dementia Australia Research Foundation over the past quarter century.

Dementia Australia Research Foundation Chair and Dementia Australia Patron Professor Graeme Samuel AC said the Foundation had spent 25 years funding revolutionary projects to expediate medical breakthrough and to improve the lives of people living with dementia.  

“During this time, they’ve enhanced our understanding of dementia at a cellular level and have developed models of care that are improving life for people living with dementia and their carers,” Professor Samuel said.

“Dementia Australia Research Foundation funds researchers across all stages of their career but maintain a particular focus on supporting Australia’s talented new and early career dementia researchers. A recent survey of grant recipients over the past 25 years found that 75 per cent were still working in dementia research and 97 per cent had mentored new researchers in the field.”

One of the researchers whose career was supercharged when she received funding from Dementia Australia Research Foundation, is Dr Rachel Buckley, who was awarded a two-year Post-Doctoral Fellowship in 2014.

Dr Buckley said the Fellowship was a huge step in her research career, which has ultimately led to her running her own laboratory at Massachusetts General Hospital, which is Harvard University’s largest teaching hospital.

It’s in this lab, in the Department of Neurology, where Dr Buckley is producing cutting-edge research on how dementia impacts men and women differently. 

“We’re one of the first groups to show that women are very different to men in their risk for pathology,” Dr Buckley explains.

“We’ve found over and again that older women show much higher levels of tau, a brain protein that becomes toxic in dementia.

“Our most recent finding is that even middle-aged women have higher levels of tau, which we think is related to menopause. The use of hormone therapy may have a dual role in reducing or increasing the risk of dementia.”

Professor Samuel said the Dementia Australia Research Foundation’s work wouldn’t be possible without the generous support of donors large and small.

All funding for Dementia Australia Research Foundation is donated by members of the public and by private and philanthropic organisations. Thank you to everyone who has donated over the past 25 years,” Professor Samuel said.

 

Navarra Venues CEO, Sal Navarra, is one such donor, who has raised more than $1 million for Dementia Australia Research Foundation since 2015.

 

The Sarina Navarra Project Grant, which is awarded through the Dementia Australia Research Foundation, was created in memory of Sal’s mother Sarina, who passed away in 2022. In 2023 the Sarina Navarra Project Grant was awarded to a project exploring if intermittent fasting may reduce the risk of developing Alzheimer’s disease.

 

“Dementia Australia does phenomenal work, and we're honoured to collaborate with them to drive innovation and improve the lives of those living with dementia,” Mr Navarra said.

Dementia Australia Patron Ita Buttrose AC OBE and a former President of the Dementia Australia Research Foundation said the Dementia Australia Research Foundation had played a significant role in enhancing our understanding of dementia over the past 25 years.

“It’s predicted that the number of Australians living with dementia will approach 800,000 in the next 35 years. However, with continued commitment and support from researchers and donors, by the time we get there, we can be closer to a medical breakthrough and, ultimately, a cure,” Ms Buttrose said.

To find out more about how you can support innovative dementia research visit donate.dementia.org.au.

 

Dementia Australia Research Foundation is the research arm of Dementia Australia, which provides funding to support new and emerging dementia researchers.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

-Ends-

Media contacts: David Gear, Media and Communications Advisor david.gear@dementia.org.au 0427 204 297

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.


Contact details:

David Gear:

david.gear@dementia.org.au

0427 204 297

 

 

Media

More from this category

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

  • Medical Health Aged Care, Science
  • 13/09/2024
  • 11:08
La Trobe University

Centre to play key role in global AI medical research

Artificial intelligence promises to unlock new cures for cancer and other diseases by revolutionising the speed, cost and availability of personally designed drugs and enabling these to be tested on “digital twins" before being given to patients. AI will enable broad-spectrum like chemotherapy to be replaced by these more personalised, better targeted treatments. Scientists at La Trobe University's new Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI), launched today, will also apply AI techniques to mRNA therapy development to enable faster design of more precise and effective treatments. Vice-Chancellor Professor Theo Farrell said ACAMI would sit within La Trobe’s…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.